ライフサイエンスコーパス: muscle biopsy

1 eated disease (symptoms for >2 months before muscle biopsy).

2 nderlying pathology on biochemistry tests or muscle biopsy.

3 synthesis rates in skeletal muscle without a muscle biopsy.

4 kness, and specific pathological features on muscle biopsy.

5 derestimated data acquired via more invasive muscle biopsy.

6 myopathy associated with inclusion bodies on muscle biopsy.

7 um of diseases associated with a necrotizing muscle biopsy.

8 or isolation of Sarcocystis species DNA from muscle biopsy.

9 sment of the same muscle with repeat MRI and muscle biopsy.

10 e frequent absence of rimmed vacuoles in the muscle biopsy.

11 arcocystis nesbitti DNA was recovered from 1 muscle biopsy.

12 d avoid issues associated with open skeletal muscle biopsy.

13 e need for invasive diagnostic tests such as muscle biopsy.

14 versally present in patients who underwent a muscle biopsy.

15 most commonly defined by changes observed in muscle biopsy.

16 ng of the gene may preclude performance of a muscle biopsy.

17 genes, which result in dystrophic changes on muscle biopsy.

18 ere was some variability for each individual muscle biopsied.

19 nalyses on protein and RNA isolated from the muscle biopsies.

20 ation in the sarcolemma, as assessed through muscle biopsies.

21 criptional profiles of MRI-guided human FSHD muscle biopsies.

22 ing (e.g. Akt/mTORC1) by immunoblotting from muscle biopsies.

23 alanine [3-13C] assessed by LC-tandem MS in muscle biopsies.

24 ntification of amyloid deposits in nerve and muscle biopsies.

25 its contribution to gene expression in FSHD muscle biopsies.

26 ever, implying a non-myogenic cell source in muscle biopsies.

27 pression profiling were performed on fat and muscle biopsies.

28 in permeabilized muscle fibres prepared from muscle biopsies.

29 alpha-dystroglycan, which can be detected in muscle biopsies.

30 mic clamp, muscle microdialysis studies, and muscle biopsies.

31 e, and the presence of tubular aggregates in muscle biopsies.

32 des, and protein expression were measured in muscle biopsies.

33 milder SMA mouse model and in human patient muscle biopsies.

34 y contribute the molecular landscape of FSHD muscle biopsies.

35 st, isokinetic muscle function, and skeletal muscle biopsies.

36 RNA expression and disease activity in FSHD muscle biopsies.

37 ons with the collection of blood samples and muscle biopsies.

38 macrophages in PAD versus non-PAD (controls) muscle biopsies.

39 single muscle fibers, or when they reside in muscle biopsies.

40 data from magnetic resonance imaging-guided muscle biopsies.

41 nal proteomic analysis of the 2 crewmembers' muscle biopsies.

42 ified 731 known and 325 novel lncRNAs in the muscles biopsies.

43 Sequential muscle biopsies (0, 2 and 6 h) were analysed using confo

44 Half of the muscle biopsies (6/12) showed myopathic changes; increas

45 The miRNome profiles of skeletal muscle biopsies acquired from four different MD groups a

46 apacity for fatty acid oxidation in skeletal muscle biopsies, along with enhanced efficiency of oxyge

47 d characterization, albeit rarely used, from muscle biopsy analysis.

48 assessed by MRI, muscle strength testing and muscle biopsy analysis.

49 se continuous tracer infusions combined with muscle biopsies and arterio-venous (A-V) studies across

50 We performed successive muscle biopsies and assessed systemic insulin sensitivit

51 Muscle biopsies and blood samples were collected to asse

52 erinsulinemic-euglycemic clamp with skeletal muscle biopsies and indirect calorimetry before and afte

53 However, DUX4 is difficult to detect in FSHD muscle biopsies and it is debatable how robust changes i

54 eport DUX4-fl mRNA and protein expression in muscle biopsies and myogenic cells from genetically unaf

55 y and Western blot in cell samples from both muscle biopsies and primary cultures.

56 n magnetic resonance spectroscopy (MRS), and muscle biopsy and fibroblasts were analyzed.

57 Muscle biopsy and immunohistochemical analysis found def

58 of muscles on imaging, myopathic changes on muscle biopsy and loss of calpain 3 protein on western b

59 Other investigations including muscle biopsy and respiratory chain enzyme activity were

60 ted disease (symptoms for </=2 months before muscle biopsy), and 17 had long duration of untreated di

61 mic clamps, magnetic resonance spectroscopy, muscle biopsies, and assessment of ex vivo mitochondrial

62 ein is rare and difficult to detect in human muscle biopsies, and pathological mechanisms are obscure

63 ed 1) OGTT, 2) euglycemic insulin clamp with muscle biopsy, and 3) (1)H-magnetic resonance spectrosco

64 f histology, immunohistochemical analysis of muscle biopsy, and candidate gene sequencing.

65 by muscle magnetic resonance imaging (MRI), muscle biopsy, and cardiac examination.

66 lower limb magnetic resonance imaging (MRI), muscle biopsy, and genetic testing.

67 bility scores, nerve conduction studies, and muscle biopsies are reported.

68 Tubular aggregates on muscle biopsy are characteristic but may not be apparent

69 Muscle biopsies at 1 year had sustained AAT expression a

70 All patients had muscle biopsies at baseline and week 48.

71 Participants had a muscle biopsy before starting treatment and after 12 wee

72 NM is defined on muscle biopsy by the presence of cytoplasmic rod-like st

73 gs from conventional investigations, such as muscle biopsy, can be misleading.

74 In calf muscle biopsies, cocoa improved mitochondrial COX (cytoc

75 ymphoblastoid cell lines is elevated in FSHD muscle biopsies compared to controls.

76 All DM2 muscle biopsies contained regenerating myofibres, with a

77 n summary, the regenerative response in FSHD muscle biopsies correlates with the severity of patholog

78 Deep sequencing of the TCR Vbeta region from muscle biopsies demonstrated a limited number of T cell

79 much larger collection of myogenic cells and muscle biopsies derived from biceps and deltoid muscles

80 an inconsistent biomarker for FSHD skeletal muscle biopsies, displaying efficacy only on pathologica

81 5]phenylalanine infusion in conjunction with muscle biopsies during basal, postabsorptive conditions

82 t myopathic features that were detectable on muscle biopsies, electromyography, muscle magnetic reson

83 muscles such as those obtained from patient muscle biopsies exhibit a significant decrease in expres

84 d later or are nonaffected; and (2) in adult muscle biopsies, FAT1 expression is lower in FSHD muscle

85 Typical muscle biopsy features included fibre size variability,

86 with autosomal dominant distal myopathy and muscle biopsy features of both minicores and nemaline ro

87 0 g protein) states after WM and ED by using muscle biopsies, fluorescence-based assays, immunoblot a

88 tion at the protein level by immunolabelling muscle biopsies for developmental myosin heavy chain.

89 of sarcopenia versus age-matched controls in muscle biopsies from 119 older men from Singapore, Hertf

90 We obtained diaphragm muscle biopsies from 22 critically ill patients who rece

91 fluence gene expression, we analyse skeletal muscle biopsies from 271 well-phenotyped Finnish partici

92 Muscle biopsies from 4 family members were used for anal

93 udies were also undertaken in human skeletal muscle biopsies from a cohort of coronary artery bypass

94 Endomyocardial and skeletal muscle biopsies from affected individuals of both famili

95 between capillary-fiber ratio (p < 0.01) in muscle biopsies from amputated limbs and Grad measured p

96 ammonia in both plasma samples and skeletal muscle biopsies from cirrhotic patients compared with he

97 An ultra-structural analysis of muscle biopsies from DMD patients suggested that the chr

98 Skeletal muscle biopsies from human patients confirmed the presen

99 Skeletal muscle biopsies from humans with metabolic syndrome afte

100 We also identified RvD2 in skeletal muscle biopsies from humans with peripheral artery disea

101 ategies in mice, together with assessment of muscle biopsies from humans, demonstrated that type I mu

102 Furthermore, human muscle biopsies from individuals who underwent modest di

103 Muscle biopsies from m. vastus lateralis were collected,

104 he myogenesis biomarker was also elevated in muscle biopsies from most independent FSHD, DM2 or Duche

105 espoke analysis for applying IMC in skeletal muscle biopsies from patients with genetically-character

106 re conducted an expression analysis of human muscle biopsies from patients with T2D; normoglycemic bu

107 This includes muscle biopsies from patients with undiagnosed rare musc

108 Using hamstring muscle biopsies from pediatric patients with CP (n =33)

109 r more regenerating myofibres in 76% of FSHD muscle biopsies from quadriceps and 91% from tibialis an

110 chondrial myopathy, we investigated skeletal muscle biopsies from seven subjects with genetically def

111 etal muscle and spinal cord of SMA mice, and muscle biopsies from SMA patients and controls, using qu

112 By assessing muscle biopsies from subjects with a range of different

113 NA methylation (DNAme) in 265 human skeletal muscle biopsies from the FUSION study with >7 million ge

114 Muscle biopsies from the m. vastus lateralis were obtain

115 Muscle biopsies from the patients showed dystrophic hist

116 Muscle biopsies from vastus lateralis muscle were obtain

117 ater than or equal to 8 underwent a skeletal muscle biopsy from the vastus lateralis at median day 5

118 Analysis of the RyR1 protein content in a muscle biopsy from this individual showed a content of o

119 s shown using meta-analysis of over six FSHD muscle biopsy gene expression studies, and validated by

120 bulbar involvement and tubular aggregates on muscle biopsy help to distinguish DPAGT1 CMS from the ma

121 cephalography (EEG), electromyography (EMG), muscle biopsy, high-resolution molecular karyotype array

122 le myopathies may have prominent necrosis on muscle biopsy, immune-mediated myopathies are emphasized

123 rst study to use cells derived from skeletal muscle biopsies in CFS patients and healthy controls to

124 o address this question, we performed serial muscle biopsies in healthy, lean subjects before and dur

125 36 individuals with FSHD, followed by needle muscle biopsies in safely accessible muscles.

126 n of cytotoxic T cells in the post-treatment muscle biopsies in the two high-dose cohorts.

127 may enable a more rapid diagnosis and avoid muscle biopsy in patients with progressive external opht

128 max) and microcirculation loss on quadriceps muscle biopsy (in CD31(+) immunofluorescence experiments

129 observation of megamitochondria in skeletal muscle biopsies is exclusive to this type of MD.

130 Muscle biopsy is commonly used as an early diagnostic to

131 The staining was performed on archival muscle biopsy material, with subject assignment to norma

132 Muscle biopsies (n = 28), obtained at the level of BOLD-

133 rasonography, electrodiagnostic studies, and muscle biopsies (n = 3).

134 of a number of histopathological findings on muscle biopsy--namely, rimmed vacuoles, an inflammatory

135 Quadriceps muscle biopsies obtained before and after 10 and 60 min

136 ted 7 days of bed rest with vastus lateralis muscle biopsies obtained before and after.

137 n sequencing to examine the transcriptome in muscle biopsies obtained from two histologically distinc

138 SINV infection ex vivo by examining a unique muscle biopsy obtained from a patient with chronic myalg

139 Data from a muscle biopsy obtained from a patient with GFPT1 mutatio

140 found reduced alpha-DG glycosylation in the muscle biopsies of affected individuals and in available

141 espiratory chain complexes, were observed in muscle biopsies of affected subjects.

142 omal pathway of intracellular proteolysis in muscle biopsies of CHF patients and healthy controls in

143 nd protein expression plus ultrastructure in muscle biopsies of lowlanders at sea level and following

144 Muscle biopsies of new onset JDM patients showed increas

145 Muscle biopsies of patients were analyzed for atrophy an

146 In muscle biopsies of patients with anti-SRP(+) and anti-HM

147 We found that muscle biopsies of patients with recessive RYR1 mutation

148 of members of the Dlk1-Dio3 miRNA cluster in muscle biopsies of the GRMD dog model.

149 Muscle biopsies of the vastus lateralis and real-time po

150 Muscle biopsy of astronaut A showed an impressive 80% in

151 = 10; and SCA patients, n = 7) and underwent muscle biopsy of the vastus lateralis.

152 bsorptiometry scan, underwater weighing, and muscle biopsy of the vastus lateralis.

153 DMD based on findings of clinical follow-up, muscle biopsy, or direct mutational testing of the DMD g

154 I and IV were assessed in peripheral blood, muscle biopsy, or postmortem brain at the level of enzym

155 sue elements were observed in seven of eight muscle biopsies performed in the irradiated field; and m

156 Muscle biopsy reliably showed severely reduced or absent

157 a clinical phenotype suggestive of CMD, with muscle biopsy reserved as a second-tier investigation.

158 iased RNA sequencing of adipose and skeletal muscle biopsies revealed fatty acid metabolism as a key

159 Skeletal muscle biopsies revealed subsarcolemmal accumulation of

160 Muscle biopsy revealed a neurogenic pattern with mitocho

161 Electron microscopy of his muscle biopsy revealed abnormal mitochondria.

162 Muscle biopsy revealed lipid accumulation, mitochondrial

163 Muscle biopsy revealed ragged red fibers; mild cerebral

164 A muscle biopsy revealed scattered myofibers with internal

165 Muscle biopsy revealed the absence of ragged-red fibers,

166 gth CFL2 transcript was also observed in the muscle biopsy sample of the patient with p.A35T mutation

167 Muscle biopsy samples (n=30) were examined by immunohist

168 ng revealed a substantial Treg population in muscle biopsy samples containing AAT-expressing myofiber

169 nome-wide DNA methylation profiling, as were muscle biopsy samples from 4 healthy controls.

170 We analyzed the expression of PDGF-BB in muscle biopsy samples from controls and patients with DM

171 t regenerating and necrotic muscle fibers in muscle biopsy samples from DMD patients expressed PDGF-B

172 e serum of four volunteers, and by RT-PCR in muscle biopsy samples from four volunteers.

173 We obtained muscle biopsy samples from patients with diabetes who we

174 tial expression of microRNA-126 (miR-126) in muscle biopsy samples from the 2 patient groups and the

175 e transcription-polymerase chain reaction in muscle biopsy samples from the 3 groups.

176 stochemical analyses were performed on human muscle biopsy samples from the patients.

177 Muscle biopsy samples from vastus lateralis and blood sa

178 To address this question, we analyzed muscle biopsy samples from young, lean, insulin resistan

179 se-induced metabolic perturbation assayed in muscle biopsy samples taken from locomotor muscle.

180 Blood and muscle biopsy samples were collected at rest and after e

181 Blood and muscle biopsy samples were collected before and after th

182 Blood and muscle biopsy samples were collected over 360 min of pos

183 emoral arterial and venous blood samples and muscle biopsy samples were collected throughout the stud

184 Repeated blood and muscle biopsy samples were collected to assess whole-bod

185 Muscle biopsy samples were obtained to determine myofibr

186 Skeletal muscle biopsy samples were taken to assess intramuscular

187 s currently assessed through methods such as muscle biopsy, serum biomarkers, functional testing, and

188 Extraocular muscle biopsy should be strongly considered whenever the

189 Muscle biopsies showed chronic denervation/reinnervation

190 Muscle biopsies showed complete loss of large supervilli

191 Muscle biopsies showed cytochrome c oxidase-negative fib

192 Subject fibroblasts and muscle biopsies showed impaired mitochondrial function,

193 Analyses of skeletal muscle biopsies showed lower messenger RNA and protein l

194 Muscle biopsies showed multiminicores and lobulated fibe

195 Muscle biopsies showed multiminicores, nemaline rods, cy

196 Muscle biopsies showed myopathic features including fibr

197 Muscle biopsies showed variability in fiber size, centra

198 In subject 1, muscle biopsy showed combined oxidative phosphorylation

199 Muscle biopsy showed dystrophic features and reduced alp

200 ne kinase was normal or mildly elevated, and muscle biopsy showed mild myopathic changes with selecti

201 In all patients, muscle biopsy showed ragged-red and cytochrome c oxidase

202 rug activity; however, only a subset of FHSD muscle biopsies shows evidence of DUX4 expression.

203 Muscle biopsy shows rods and fiber type disproportion.

204 In all subjects, MTL adjusted for muscle biopsy site (MTLA) was longer than LTL and the LT

205 A muscle biopsy specimen was myopathic with a lack of myop

206 Histological assessment of a muscle biopsy specimen was performed in 1 patient, and q

207 ein levels were measured in human and rodent muscle biopsy specimens after 1 bout of exercise.

208 he findings, especially those related to the muscle biopsy specimens and electromyography, were consi

209 to 39-kDa protein in all 4 diseased skeletal muscle biopsy specimens and in cardiac tissue.

210 Muscle biopsy specimens demonstrated type I fiber atroph

211 Muscle biopsy specimens from 38 of 225 patients showed p

212 btained muscle fiber fragments from skeletal muscle biopsy specimens from adult donors aged 20 to 80

213 Immunohistological and RT-PCR analysis of muscle biopsy specimens from anti-MDA5 and classic DM we

214 naling molecules were determined in skeletal muscle biopsy specimens from BMI- and age-matched overwe

215 High levels of moesin were also observed in muscle biopsy specimens from DMD, Ullrich CMD, and meros

216 Age-matched controls consisted of muscle biopsy specimens from healthy children aged 1 to

217 ession of nucleolar protein 66 (NO66), as do muscle biopsy specimens from patients with CKD or those

218 Muscle biopsy specimens from patients with XLMTM exhibit

219 ream targets ACC-beta, TBC1D1, and TBC1D4 in muscle biopsy specimens obtained from 13 overweight/obes

220 Skeletal muscle biopsy specimens revealed nonspecific myopathic c

221 Muscle biopsy specimens showed markedly thickened endoth

222 Muscle biopsy specimens were obtained at baseline and 3

223 Muscle biopsy specimens were obtained from the vastus la

224 roximately 18,000 genes in each of 113 human muscle biopsy specimens, and studied biopsy specimens an

225 h dystrophic or myopathic changes present in muscle biopsy specimens.

226 muscle metabolism were measured in skeletal muscle biopsy specimens.

227 and Western blot analysis were performed on muscle biopsy specimens.

228 mary myotubes prepared from vastus lateralis muscle biopsy specimens.

229 ter baseline bilateral vastus lateralis (VL) muscle biopsies, subjects consumed 150 ml D2 O (70 atom%

230 ter baseline bilateral vastus lateralis (VL) muscle biopsies, subjects consumed 150 ml D2O (70 atom p

231 Skeletal muscle biopsies taken 24 h after the HIIT exercise showe

232 fusion), and 3) saline control with skeletal muscle biopsies taken just before, 30 min after, and 75

233 Before and after intervention, muscle biopsies, tests of functional capacity, and quali

234 rimental measurements show that in PAD human muscle biopsies the VEGF165b isoform is at least as abun

235 hypothesis, transcriptomics data from human muscle biopsy tissue revealed misregulation of the AMP-a

236 In muscle biopsy tissues from anti-HMGCR-positive patients,

237 en performed 3 min all-out tests and donated muscle biopsies to test the second hypothesis.

238 Genet., 29, 1030-1043] performed MRI, muscle biopsy transcriptomics and histopathology on a co

239 Human skeletal muscle biopsies transplanted into the anterior tibial co

240 ify senescent cells in frozen human skeletal muscle biopsies using these markers to determine the eff

241 In human PAD versus control muscle biopsies, VEGF165b: (1) is elevated, (2) is bound

242 METHODS AND In human PAD versus control muscle biopsies, VEGF165b: (1) is elevated, (2) is bound

243 Biochemical analysis of existing muscle biopsies was correlated with the severity of the

244 Insulin and protein signaling in muscle biopsies was not affected by TNF-alpha.

245 n of l-[ring-13C6]-phenylalanine with serial muscle biopsies was used to determine postabsorptive and

246 of l-[ring-(13)C6] phenylalanine with serial muscle biopsies was used to measure MPS under baseline f

247 A muscle biopsy was analyzed by light and electron microsc

248 In the muscle biopsy we found evidence of muscle regeneration d

249 Muscle biopsies were also sampled before and 1 h after t

250 Skeletal muscle biopsies were analysed for mitochondrial volume d

251 Skeletal muscle biopsies were collected before and after the inte

252 Muscle biopsies were collected during a constant stable

253 between NDD-CKD and HC populations, skeletal muscle biopsies were collected from the vastus lateralis

254 Muscle biopsies were collected prior to and at 3, 24, an

255 Muscle biopsies were collected prior to the meal and at

256 Additionally, muscle biopsies were collected to assess muscle lipid (f

257 Probands' muscle biopsies were dystrophic, and serum creatine kina

258 Muscle biopsies were obtained 3 hours, 2 days, and 27 da

259 Muscle biopsies were obtained 4 and 24 h after the 1st,

260 tentials after direct muscle stimulation and muscle biopsies were obtained at median days 7 and 5, re

261 and eight controls, serial vastus lateralis muscle biopsies were obtained before and 7 hours after a

262 Vastus lateralis muscle biopsies were obtained before and immediately aft

263 Muscle biopsies were obtained from m. vastus lateralis t

264 For this purpose, skeletal muscle biopsies were obtained from nine lowlanders at se

265 Basal muscle biopsies were obtained from seven obese (BMI >40

266 Muscle biopsies were obtained from the m.

267 Muscle biopsies were obtained from the vastus lateralis

268 Muscle biopsies were obtained from two cohorts of contro

269 Two hours after cryotherapy, muscle biopsies were obtained to analyze changes in the

270 and after the intervention, vastus lateralis muscle biopsies were obtained.

271 Muscle biopsies were performed after 6 wk of training.

272 glycemic-hyperinsulinemic clamp and skeletal muscle biopsies were performed in 73 individuals encompa

273 Muscle biopsies were performed to assess between-group d

274 ps and in vitro analyses of vastus lateralis muscle biopsies were performed.

275 and genetic data as well as muscle MRIs and muscle biopsies were reviewed.

276 Muscle biopsies were stained for galactose-alpha1,3-gala

277 WDM muscle biopsies were studied by Western blotting and imm

278 Muscle biopsies were taken and mitochondrial respiration

279 after 50 ml week(-1) ), further bilateral VL muscle biopsies were taken at 3 and 6 weeks to quantify

280 Further bilateral VL muscle biopsies were taken at 3 and 6 wk to temporally q

281 Muscle biopsies were taken at rest and every approximate

282 Muscle biopsies were taken before and after each clamp.

283 Muscle biopsies were taken before and after training fro

284 Muscle biopsies were taken before and after training to

285 Muscle biopsies were taken from 64 old or young male sub

286 00 ECs of the knee extensors with 1 leg, and muscle biopsies were taken from both legs 3 h post-EC.

287 In six of the subjects, muscle biopsies were taken from both legs before and aft

288 Muscle biopsies were taken from eight Trained, Lean sede

289 Muscle biopsies were taken from the m.

290 Muscle biopsies were taken from the m. vastus lateralis

291 Muscle biopsies were taken from the vastus lateralis bef

292 Muscle biopsies were taken to perform high-resolution re

293 Muscle biopsies were used for the isolation of mitochond

294 Ingested (2)H2O and skeletal muscle biopsies were used to measure the 3-d integrated

295 Muscle biopsies were within normal limits or showed non-

296 e, or nonsense DMD mutations, with available muscle biopsy Western blot data, were included irrespect

297 ation identified by histological analysis on muscle biopsies, while our two late DUX4 target gene exp

298 ne myopathy have a predominantly necrotizing muscle biopsy with minimal lymphocytic infiltration.

299 etal muscle dysfunction and a non-dystrophic muscle biopsy with the presence of one or more character

300 gnetic resonance imaging-directed diagnostic muscle biopsies yielded samples from 20 children with ju